Phase II study of neoadjuvant imatinib in glioblastoma: Evaluation of clinical and molecular effects of the treatment

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 6258-6266

  Razis, Evangelia ^a   Selviaridis, Panayotis ^b   Labropoulos, Stephanos ^a   Norris, Jeremy L ^d   Zhu, Mei Jun ^e   Song, David D ^e   Kalebic, Thea ^f   Torrens, Michael ^a   Kalogera Fountzila, Anna ^b   Karkavelas, George ^c   Karanastasi, Sofia ^c   Fletcher, Jonathan A ^e   Fountzilas, George ^c  

^a HYGEIA HOSPITAL   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Protein Discovery Inc   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B;

ADJUVANT CHEMOTHERAPY; ANTIGEN EXPRESSION; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR BIOPSY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLIOBLASTOMA; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ONCOGENE PROTEIN V-AKT; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 70349694368     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1867     Document Type: Article

References (36)

1. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 2003;3:595-614.
2. Holdhoff M, Kreuzer KA, Appelt C, et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005;34:181-185 (Pubitemid 40250495)
3. Omuro AMP, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007;6: 1909-1919 (Pubitemid 47052481)
4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037 (Pubitemid 32267972)
5. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with ametastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056 (Pubitemid 32267975)
6. Labropoulos SV, Razis ED. Imatinib in the treatment of dermatofibrosarcoma protuberans. Biologics 2007;1:347-353
7. Sihto H, Tynninen O, Butzow R, Saarialho-Kere U, Joensuu H. Endothelial cell KIT expression in human tumors. J Pathol 2007;211:481-488 (Pubitemid 46332560)
8. Hagerstrand D, Hesselager G, Achterberg S, et al. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 2006;25:4913-4922 (Pubitemid 44201182)
9. Oertel S, Krempien R, Lindel K, et al. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec). Strahlenther Onkol 2006;7:400-407 (Pubitemid 44025008)
10. Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report. Neuro Oncol 2007;9:145-160
11. Wen PY, Yung WKA, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12:4899-4907 (Pubitemid 44338577)
12. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005;23:9359-9368
13. Guetens G, Prenen H, De Boeck G, et al. Imatinib tumor tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry. J Sep Sci 2006;29:453-459
14. Fountzilas G, Karkavelas G, Kalogera-Fountzila A, et al. Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res 2006;26: 4675-4686
15. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147:9-19.
16. Titier K, Picard S,Ducint D, et al.Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005;27:634-640 (Pubitemid 41437643)
17. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005;55:379-386
18. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;15,61:8118-8121 (Pubitemid 33091601)
19. Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004;13:3999-4006. (Pubitemid 38747928)
20. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44: 879-894
21. Desjardins A, Quinn JA, Vredenburgh JJ, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 2007;83:53-60. (Pubitemid 46647165)
22. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25: 4722-4729 (Pubitemid 350086473)
23. Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R. Increased sensitivity to the platelet- derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and sti571-induced Akt inactivation. J Cell Physiol 2006;208:220-228 (Pubitemid 43849008)
24. Quick QA, Gewirtz DA. Enhancement of radiation sensitivity, delay of proliferative recovery after radiation and abrogation of MAPK (p44/42) signaling by imatinib in glioblastoma cells. Int J Oncol 2006;29:407-412
25. Gross D, Bernhardt G, Buschauer A. Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity. J Cancer Res Clin Oncol 2006;132: 589-599 (Pubitemid 44078528)
26. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000;60:5143-5150 (Pubitemid 30739772)
27. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480 (Pubitemid 34879334)
28. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Review. Curr Opin Hematol 2004;11: 35-43. (Pubitemid 38021719)
29. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985;313:144-147 (Pubitemid 15192341)
30. Lee JC, Vivanco I, Beroukhim R, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006;3:485. (Pubitemid 46028511)
31. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024 (Pubitemid 41609094)
32. Habeler C, Gelpi E, Marosi C, et al. Immunohistochemical analysis of platelet-derived growth factor receptor-a, -β, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol 2006;76:105-109 (Pubitemid 43125736)
33. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms-an update on the multidisciplinary of management of malignant glioma. Oncologist 2006;11:165-180 (Pubitemid 43261763)
34. Strommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-290 (Pubitemid 47574858)
35. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 2007;25:2601-2606
36. Raymond E, Brandes AA, Dittrich C, et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008;26:4659-4665